- BIIB -2.83%
Analyst Report: Biogen Inc.
Yahoo Finance · 1 day ago
Search results
Biogen is a leading global biotechnology company that pioneers science and drives innovations for complex and devastating diseases. Biogen is advancing a pipeline of potential therapies across neurology, neuropsychiatry, specialized immunology and rare disease and remains acutely focused on its purpose of serving humanity through science while ...
- 225.43Add to watchlist-6.56 (-2.83%)At close: Fri. Jun 7, 2024 4:00 PM EDT · Nasdaq Real Time Price (USD) · Market closed
- Open230.61High230.74Low224.66
- Mkt Cap32.82BP/E (TTM)28.18Div & YieldN/A & N/A
- Prev. Close231.9952 Wk. Low189.4452 Wk. High319.76
What analysts are sayingTop storiesRelated stocks
Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the discovery, development, and delivery of therapies for the treatment of neurological diseases to patients worldwide. Biogen operates in Argentina, Brazil, Canada, China, France, Germany, Hungary, India, Italy, Japan ...
Founded in 1978, Biogen has pioneered multiple breakthrough innovations including a broad portfolio of medicines to treat multiple sclerosis, the first approved treatment for spinal muscular atrophy, and two co-developed treatments to address a defining pathology of Alzheimer’s disease.
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally.
Apr 25, 2023 · The Food and Drug Administration on Tuesday authorized the first drug for a rare genetic form of the neurological disorder A.L.S., despite uncertainty about the treatment’s effectiveness.
Everyone at Biogen contributes to our mission to create transformative medicines for people who need them the most. Explore our business areas to discover where you can make an impact on our team.
May 16, 2024. Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis. May 14, 2024. Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI® (lecanemab-irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Under the Fast Track ...
Jun 7, 2021 · The Food and Drug Administration on Monday approved Biogen ’s Alzheimer’s disease drug aducanumab, making it the first medication cleared by U.S. regulators to slow cognitive decline in people ...
Sep 29, 2023 · TOFIDENCE (BIIB800) becomes the first tocilizumab biosimilar to gain FDA approval in the United States. FDA approval is based on a robust analytical, non-clinical and clinical data package comparing TOFIDENCE to the reference product ACTEMRA.
Founded in 1978, Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patients’ lives and to create value for shareholders and our ...
